Precision Wealth Strategies LLC Takes Position in Medpace Holdings, Inc. $MEDP

Precision Wealth Strategies LLC acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,524 shares of the company’s stock, valued at approximately $784,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Norges Bank purchased a new stake in shares of Medpace during the second quarter valued at $66,597,000. Clarkston Capital Partners LLC purchased a new position in shares of Medpace in the second quarter worth approximately $40,569,000. Mawer Investment Management Ltd. lifted its position in shares of Medpace by 17.4% in the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after acquiring an additional 121,213 shares in the last quarter. Bares Capital Management Inc. boosted its stake in Medpace by 319.2% in the 2nd quarter. Bares Capital Management Inc. now owns 157,084 shares of the company’s stock worth $49,302,000 after purchasing an additional 119,608 shares during the period. Finally, JPMorgan Chase & Co. grew its position in Medpace by 79.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 265,270 shares of the company’s stock worth $83,258,000 after purchasing an additional 117,301 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of MEDP opened at $572.00 on Friday. The firm has a market cap of $16.11 billion, a PE ratio of 40.00, a PEG ratio of 2.16 and a beta of 1.43. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $626.26. The firm’s 50 day moving average price is $578.83 and its 200 day moving average price is $478.30.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. During the same quarter last year, the firm earned $3.01 EPS. Medpace’s revenue for the quarter was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on MEDP. Rothschild Redb lowered Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd. Truist Financial set a $555.00 target price on Medpace in a report on Monday, October 27th. Mizuho increased their price target on shares of Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a research report on Friday, October 24th. Zacks Research raised shares of Medpace from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 27th. Finally, Robert W. Baird set a $613.00 price objective on shares of Medpace in a research note on Friday, October 24th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $490.82.

Insiders Place Their Bets

In other news, CFO Kevin M. Brady sold 3,000 shares of Medpace stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $590.35, for a total value of $1,771,050.00. Following the transaction, the chief financial officer owned 6,000 shares of the company’s stock, valued at $3,542,100. This trade represents a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO August J. Troendle sold 668 shares of the company’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total transaction of $394,580.92. Following the sale, the chief executive officer directly owned 646,184 shares of the company’s stock, valued at approximately $381,694,426.96. This represents a 0.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 387,925 shares of company stock valued at $233,386,647 over the last quarter. Insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.